Notice of Results

RNS Number : 3901E

Syncona Limited

27 October 2022

 

Syncona Limited

Notice of Interim Results

27 October 2022

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, will announce its interim results for the period ended 30 September 2022 on Thursday 17 November 2022.

A presentation for analysts will take place at 9.00am GMT and the webcast will be available on the Company's website at https://www.synconaltd.com/ or via this link . Alternatively, please contact [e-mail] for further details.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clark / Fergus Witt

Tel: +44 ( 0) 20 3981 7940

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Julia Bradshaw / Tim Stamper

Tel: [phone]

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by founding and building companies to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

 

END

 

 

NORBKOBPNBDDOKB